EpicentRx’s Oncolytic Virus-delivered TGFβ Inhibitor, AdAPT-001, Receives FDA Fast Track Designation for Recurrent or Refractory Soft Tissue Sarcoma Treatment

by EpicentRx | Dec 5, 2024 | Blog

AdAPT-001 received Fast Track Designation. So, what, you say? So, let’s dance. Click on the image to play.

EpicentRx’s Oncolytic Virus-delivered TGFβ Inhibitor, AdAPT-001, Receives FDA Fast Track Designation for Recurrent or Refractory Soft Tissue Sarcoma Treatment

by EpicentRx | Dec 4, 2024 | Blog

How alright are we about AdAPT-001 Fast Track Designation? Click on the image to play and find out. https://www.tiktok.com/t/ZP8NFyJ9C/

EpicentRx Word of the Week (WOW): Cozen

by EpicentRx | Dec 2, 2024 | Blog

“My Cozen Vinnie” Cozen Definition (verb): to trick, deceive, or wheedle “He cozened money out of his guardian.”; the car salesman is a cozener, he cozens his customers into buying lemons off the lot”; “he cozened his mom into doing the dishes for him”. Pronunciation:...

Make America Late Again

by EpicentRx | Nov 27, 2024 | Blog

“Better late than never” is an oldie but goodie. If we’ve said that line once, we’ve said it 100 times about lead EpicentRx therapy, AdAPT-001, plus an immune checkpoint inhibitor (ICI). That’s because AdAPT-001 and the ICI are almost always (unfashionably) late to...

Thanksgiving E-Cards

by EpicentRx | Nov 26, 2024 | Blog